Pq Bypass

Doctors Perform ‘Bypass’ Without Surgery

Seroba’s investee company, PQ Bypass was making eye-catching headlines in the USA this week.  Arkansas Heart Hospital is the first U.S. hospital to perform the DETOUR procedure and the story was carried on Little Rock’s news source, ArkansasMatters.

You can watch a video of the story here and read the full ArkansasMatters story below.

Doctors Perform “Bypass” Without Surgery.

Little Rock, Ark. – Feb., 2018 – The Arkansas Heart Hospital has been performing open surgical bypasses for years.  This month, doctors performed a bypass without surgery.

New technology is appealing for patients with peripheral artery disease (PAD), who experience a blood clot in the leg.

Cardiologist Dr. Vasili Lendel says,”It does not require actual surgery. We do not cut anything. It’s done through tiny needles percutaneously.”

It’s called the DETOUR procedure.

Dr. Vasili Lendel says they are able to deliver the bypass through the vein with tiny needles.

Arkansas Heart Hospital became the first in the nation to successfully perform it in the United States.

“Our research department has been at the forefront of medical research,” says Dr. Lendel, “And we were able to recruit patients first.”

Right now, the DETOUR procedure is in clinical trial for three years.

The non-invasive treatment has been done successfully in Europe, and is now awaiting approval in the U.S.

Dr. Lendel says about 8 million people in the U.S. have PAD. Two-thirds are asymptomatic. If they do develop symptoms, Lendel says about 5 to 6 percent of those people will end up having an amputation.

“The DETOUR trial will allow patients to return to their normal activities within a day or two and we believe it will avoid amputations,” says Dr. Lendel.

Dr. Lendel believes this type of technology will bring the number of amputations down.

The Arkansas Heart Hospital is thrilled to be a part of this clinical trial.

“It was quite the competition here in the United States,” says Dr. Lendel. “Who will be the first to be able to perform the surgery?  That’s why we are so proud and happy to be the first one. ”

Ends.

For more information on DETOUR and PQ Bypass, please click here

Recent Articles

STORM Therapeutics Logo

STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

22 October 2020, Cambridge, UK: Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development […]

Read More
STORM Therapeutics Logo

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy.

Dublin, Ireland.  9 September 2020.  FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, […]

Read More
Pq Bypass

PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device.

MILPITAS, Calif. – September 2, 2020 – PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment […]

Read More
Susan Trent Photo

Atlantic Therapeutics appoints Susan Trent as new CEO, based in the United States.

Galway, Ireland.   Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top